RP Cure Tracker

Trials / NCT02338973

Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)

Terminated Phase 1 / Phase 2 Drug / neuroprotection

Sponsor
National Eye Institute (NEI)
Treatment
Interferon gamma-1b
Gene
NR2E3
Conditions
Inherited Ophthalmic Diseases, Inherited Retinal Degeneration
Ages
12 Years to no upper limit
Enrollment
4 participants
Started
2015-01-14
Main results expected
2018-06-01
Results posted
Yes
Record last updated
2019-08-13

What the study is testing

Background:

- People with rod-cone dystrophy (RCD) or enhanced S-cone syndrome (ESCS) have excess fluid under the retina of their eye. This can cause vision loss. The medicine interferon gamma-1b may help people with these diseases.

Objectives:

- To see if interferon gamma-1b eyedrops are safe for people with RCD or ESCS. To see if the medicine can decrease retina fluid and help prevent vision loss.

Eligibility:

- People at least 12 years old with RCD or ESCS. Those with ESCS must have two mutations in the NR2E3 gene.

Design:

Where it runs

United States (1)

Open on ClinicalTrials.gov for contacts and eligibility